BiotechTube
MaxWell Biosystems

MaxWell Biosystems

Zurich, Switzerland· Est.
mxwbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

MaxWell Biosystems is a Zurich-based company founded in 2017, specializing in next-generation electrophysiology tools for neuroscience and drug discovery. Its core technology consists of high-density microelectrode arrays (HD-MEAs) that enable unprecedented resolution for recording and stimulating neuronal networks, from population-level activity down to subcellular dynamics. The company offers two main product platforms, MaxOne (single-well) and MaxTwo (24-well), which are used by academic and industrial researchers to characterize brain models, screen compounds, and interface with engineered tissues. MaxWell operates as a platform technology company, selling instruments and consumables to advance both fundamental research and applied neuropharmacology.

Neuroscience

Technology Platform

High-density microelectrode array (HD-MEA) systems for high-resolution recording and stimulation of neuronal network activity in vitro. Platforms include single-well (MaxOne) and multi-well (MaxTwo) configurations designed for detailed characterization and scalable screening.

Opportunities

The growing adoption of complex human cell-based models (e.g., brain organoids) for disease research and drug discovery creates a strong demand for high-content functional assays like HD-MEA.
Integration of AI/ML for automated analysis of massive electrophysiology datasets presents a significant value-adding opportunity.
Expansion into standardized neurotoxicity and safety pharmacology screening for pharmaceutical and chemical industries offers a large addressable market.

Risk Factors

Competition from established electrophysiology tool providers and alternative imaging technologies requires continuous demonstration of superior value.
The capital-intensive nature of hardware development and the need for a global commercial footprint pose financial execution risks.
Market growth is partially dependent on the broader, yet unproven, adoption of complex in vitro neural models in industrial drug discovery pipelines.

Competitive Landscape

MaxWell competes in the electrophysiology tools market against companies like Axion BioSystems (multi-well MEA systems) and Multi Channel Systems MCS GmbH (traditional and high-density MEAs). Its key differentiation is the exceptionally high electrode density and signal quality of its platforms, aimed at the high-resolution, single-neuron analysis segment. It also faces indirect competition from optical methods (calcium imaging) and automated patch clamp systems for functional screening.

More companies in Neuroscience & CNS →More companies in Switzerland →